









Markets
/
Stocks
/
nasdaq-arvn
/

Arvinas Inc

ARVN

10.630USD

+0.630+6.30%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

752.60MMarket Cap

LossP/E TTM



Arvinas Inc

10.630

+0.630+6.30%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Arvinas Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and strong technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Arvinas Inc's Score

Industry at a Glance

Industry Ranking

42 / 407

Overall Ranking

140 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 20 analysts

Buy

Current Rating

12.688

Target Price

+19.36%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Arvinas Inc Highlights

StrengthsRisks

Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 100.46% year-on-year.

Undervalued

The company’s latest PE is -13.11, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 69.26M shares, decreasing 25.93% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 128.03K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 5.90, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 41.90M, representing a year-over-year decrease of 59.08%, while its net profit experienced a year-over-year decrease of 28.66%.

Score

Industry at a Glance

Previous score

5.90

Change



Financials

6.31

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.26

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.22

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Arvinas Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 8.32, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -13.11, which is -80.37% below the recent high of -2.57 and -12.07% above the recent low of -14.69.

Score

Industry at a Glance

Previous score

8.32

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 42/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 7.20, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Arvinas Inc is 13.00, with a high of 21.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

7.20

Change

Support & Resistance

No Data

Analyst Rating

Based on 20 analysts

Buy

Current Rating

12.688

Target Price

+19.36%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Arvinas Inc

ARVN

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 8.45, which is higher than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 11.29 and the support level at 9.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.78

Change

1.67

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.036

Buy

RSI(14)

67.905

Neutral

STOCH(KDJ)(9,3,3)

80.591

Buy

ATR(14)

0.462

High Vlolatility

CCI(14)

186.092

Buy

Williams %R

4.142

Overbought

TRIX(12,20)

0.432

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

9.892

Buy

MA10

9.827

Buy

MA20

9.660

Buy

MA50

8.826

Buy

MA100

8.149

Buy

MA200

9.453

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 94.34%, representing a quarter-over-quarter decrease of 5.73%. The largest institutional shareholder is The Vanguard, holding a total of 9.38M shares, representing 12.78% of shares outstanding, with 24.68% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

9.38M

+12.34%

BlackRock Institutional Trust Company, N.A.

5.26M

+4.39%

Citadel Advisors LLC

3.67M

-5.20%

Pfizer Inc

3.46M

Logos Global Management LP

4.80M

+45.45%

D. E. Shaw & Co., L.P.

2.15M

Millennium Management LLC

1.90M

+44.85%

State Street Investment Management (US)

1.73M

-8.64%

Opaleye Management Inc.

1.68M

-14.94%

New Leaf Venture Partners LLC

1.59M

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 5.68, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 2.47. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.